Latest Mitral regurgitation Stories
KIRKLAND, Wash., May 4, 2011 /PRNewswire/ -- Cardiac DimensionsÂ®, Inc. announced today the initiation of two new clinical studies using the CARILLONÂ® Mitral Contour System(TM), an investigational device for percutaneous treatment of Functional Mitral Regurgitation (FMR).
Measuring oxidative stress may help doctors predict the risk of developing atrial fibrillation, the most common heart beat irregularity.
NorthShore University HealthSystem's Ted Feldman, MD, Presents Late Breaking Data at American College of Cardiology Conference EMBARGOED FOR RELEASE UNTIL 8 AM, CDT, APRIL 4, 2011 EVANSTON, Ill., April 4, 2011 /PRNewswire-USNewswire/ -- NorthShore University HealthSystem (NorthShore) interventional cardiologist, Ted Feldman, MD, presented positive results from the EVEREST II trial (Endovascular Valve Edge-to-Edge REpair STudy), that were concurrently published in The New England Journal of...
NEW ORLEANS, April 4, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced data from its EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) study showing that patients with significant mitral regurgitation (MR) treated with the company's investigational percutaneous catheter-based MitraClipÂ® system continue to demonstrate the clinical benefits of initial treatment shown at one year out to two years, including improvements in heart function and reductions in symptoms.
NYU Langone Medical Center surgeons are performing minimally invasive heart surgery techniques on patients in their 80s and 90s.
ABBOTT PARK, Ill., March 30, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the launch of the company's catheter-based MitraClipÂ® system for the treatment of mitral regurgitation (MR) in Australia.
Cardiac Surgery Market to Reach Over $4.4 Billion by 2017 VANCOUVER, Jan.
A percutaneous mitral valve clip designed to stop mitral valve regurgitation demonstrated clinical benefit as measured by the degree of mitral regurgitation.
KIRKLAND, Wash., Aug.
PARIS, May 25 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced new data from the landmark EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) trial, which provide additional details about the safety and clinical benefit of Abbott's investigational MitraClipÂ® system for the two causes of mitral regurgitation (MR) - functional MR (FMR) or degenerative MR (DMR).
- totally perplexed and mixed up.